OH-PARKER-AEROSPACE
24.4.2024 16:01:32 CEST | Business Wire | Press release
Parker Aerospace, a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, will participate in the HyFIVE consortium of industry and academic partners developing a world-leading liquid hydrogen fuel system and supply chain supporting zero-emission aviation in the 2030s.
In addition to Parker Aerospace, HyFIVE includes fellow industry partners Marshall and GKN Aerospace, as well as academic partners University of Manchester, University of Bath and Cardiff University. The project is supported by the ATI Programme, a partnership between the UK’s Department for Business and Trade, the Aerospace Technology Institute (ATI) and Innovate UK (UKRI). The consortium will receive initial funding of £17 million ($21.5 million) from industry, matched by £20 million ($25 million) from the UK Government.
A path to zero emissions flight
The objective of the HyFIVE consortium is to develop, test and validate a modular and scalable cryogenic hydrogen fuel system architecture appropriate for multiple types of aircraft, and support of hydrogen electric propulsion or hydrogen combustion powertrains. The initiative will address technology development for hydrogen fuel systems in five key areas: storage, conveyance, indication, fueling and venting.
Collaboration among industry leaders
Parker Aerospace, which includes Parker Meggitt, has a broad spectrum of solutions for both airframes and engines and will furnish its advanced technology and expertise in the areas of sensing, thermal management and fluid conveyance.
Marshall will be leading the HyFIVE efforts, providing its expertise in complex system design, integration and certification, honed over decades of delivering aircraft fuel systems and complex aircraft modification projects.
GKN Aerospace, specializing in the design, manufacture and assembly of aircraft structures, engine components and systems, will contribute its industry-leading advanced materials and hydrogen cryogenic system optimization expertise.
Academic partners University of Manchester, University of Bath and Cardiff University have been selected for their world-leading research capabilities and advanced testing facilities in the areas of hydrogen-electric propulsion, cryogenic applications, power transmission, turbomachinery and next-generation material development.
Technical program detailed
The HyFIVE consortium members have defined a full technical program spanning several years, from initial architecture development and supplier engagement to ground testing and final design review for the integrated fuel system.
By 2027, the consortium plans to:
- Develop and validate an integrated family of mature fuel system technologies and capabilities conducive to certification.
- Conduct ground demonstration of an integrated fuel system encompassing the storage, conveyance, indication, venting and fueling systems.
- Open a range of flight demonstration and exploitation paths with prospective customers.
- Develop a customer-ready supply chain and industrialization strategy.
The timely achievement of these objectives will support the successful introduction of a new generation of zero-emissions aircraft in the 2030s.
"Parker is fully committed to sustainability, which is why we are making focused investments in innovative, next-generation technologies,” said Tracy Rice, vice president of technology and innovation for Parker Aerospace. “Hydrogen fuel systems play a critical role in achieving zero emissions in aviation and working with our partners on this project will enable us to further advance our expertise in this area and drive the development of innovative solutions that support a more sustainable future.”
About Parker Aerospace. At Parker Aerospace, we develop technologies and innovative solutions that enable reliable, efficient and increasingly sustainable flight for the lifecycle of the aircraft, including aftermarket support. Parker stands at the forefront of aviation technology with an expanded range of products and services that sits nose-to-tail across the entire aircraft. Our passionate people with deep engineering expertise, together with our breadth of differentiated technologies, ensure that we make the extraordinary happen and continue to shape the future of aviation in partnership with our customers.
About Parker Hannifin. Parker is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Learn more at www.parker.com or @parkerhannifin.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424285169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom